Fiona Rudkin gained a BSc (Hons) degree in Pharmacology with Industrial Experience from The University of Edinburgh in 2008 before completing an MSc in Neuroscience in 2009 at the University of Aberdeen. Following this, Fiona worked in the Global Biotherapeutics Division at Pfizer Ltd on early-stage drug discovery programmes before obtaining her PhD in Microbiology from the University of Aberdeen in 2015. Her PhD and subsequent postdoctoral research focused on generating and validating human antibodies as new therapeutics for life-threatening and multi-drug resistant infections. In 2017, Dr. Rudkin was awarded a Royal Society of Edinburgh Enterprise Fellowship followed in 2018 by funding from the Scottish Enterprise High Growth Spinout Programme to commercialize this research. Recently she was awarded a Wellcome Innovator Award to advance fungal therapeutic antibody programmes and lead the creation of mycoBiologics – a new biotech company dedicated to improving the survival of patients suffering from life-threatening, drug-resistant infections.